Samsung Biologics Reports Second Quarter 2026 Financial Results

Samsung Biologics announced its financial results for the second quarter of fiscal year 2026, ending in July. The company recorded revenue of KRW 1,321 billion and an operating profit of KRW 586 billion. These results reflect stable manufacturing operations across its facilities and disciplined execution on ongoing client programs.

For the first half of 2026, Samsung Biologics posted a combined revenue of KRW 2,578 billion and an operating profit of KRW 1,167 billion. The company's cumulative contract value reached USD 21.6 billion, indicating sustained demand for its integrated development and manufacturing services from global clients.

Expansion efforts continued during the quarter. The integration of its newly acquired manufacturing facility in Rockville, Maryland, USA, proceeded as planned, and Plant 5 remained on track for its ramp-up. Additionally, a new sales office was opened in the Netherlands to enhance client proximity and support in Europe.

Samsung Biologics also advanced its innovation initiatives through its Life Science Fund, making investments in areas such as genomics-based antigen discovery and oncology drug development. The company anticipates achieving the upper end of its previously announced 2026 guidance and is undertaking a public tender offer to acquire PolyPeptide Group to broaden its portfolio into peptide therapeutics.